Compare · MEDP vs PPD
MEDP vs PPD
Side-by-side comparison of Medpace Holdings Inc. (MEDP) and PPD, Inc. (PPD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MEDP and PPD operate in Biotechnology: Commercial Physical & Biological Resarch (Health Care), so they compete in similar markets.
- PPD is the larger of the two at $16.64B, about 1.3x MEDP ($12.97B).
- MEDP has hit the wire 10 times in the past 4 weeks while PPD has been quiet.
- MEDP has more recent analyst coverage (25 ratings vs 1 for PPD).
- Company
- Medpace Holdings Inc.
- PPD, Inc.
- Price
- $454.36-0.89%
- $47.29-0.07%
- Market cap
- $12.97B
- $16.64B
- 1M return
- +6.48%
- -
- 1Y return
- +52.44%
- -
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- Biotechnology: Commercial Physical & Biological Resarch
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2016
- 2020
- News (4w)
- 10
- 0
- Recent ratings
- 25
- 1
Medpace Holdings Inc.
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It also provides clinical development services to the biotechnology, pharmaceutical, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. The company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.
PPD, Inc.
PPD, Inc., together with its subsidiaries, provides drug development services to the biopharmaceutical industry worldwide. The company operates through two segments, Clinical Development Services and Laboratory Services. It offers clinical development services, including product development and consulting, early development, Phases II-IV clinical trial management, accelerated enrollment, peri-and post-approval, and medical communications services. The company also provides laboratory services comprising bioanalytical, biomarker, vaccine science, good manufacturing practice, and central laboratory services. It serves pharmaceutical, biotechnology, medical device, and government organizations, as well as other industry participants. The company has a collaboration with Science 37 to design, build, test, implement, and execute digital trials using Science 37's DCT SaaS-based technology platform. PPD, Inc. was founded in 1985 and is headquartered in Wilmington, North Carolina.
Latest MEDP
- New insider Hansman Brad W. claimed ownership of 697 shares (SEC Form 3)
- SEC Form 8-K filed by Medpace Holdings Inc.
- General Counsel & Corp. Secy. Ewald Stephen P exercised 16,349 shares at a strike of $138.87 and sold $7,357,050 worth of shares (16,349 units at $450.00) (SEC Form 4)
- SEC Form 8-K filed by Medpace Holdings Inc.
- SEC Form 4 filed by Director Zander Dani S.
- SEC Form 4 filed by Director Mccarthy Cornelius P. Iii
- SEC Form 4 filed by Director Kraft Robert O.
- SEC Form 4 filed by Director Gwadry-Sridhar Femida H.
- SEC Form 4 filed by Director Davenport Fred B Jr
- SEC Form 4 filed by Director Carley Brian T
Latest PPD
- InnoCare Pharma Goes Back to Funding Trough With STAR Market Listing
- Saama Appoints Scott Rogers as Company's Chief Financial Officer
- SEC Form 15-12B filed by PPD, Inc.
- SEC Form 4: Carlyle Group Inc. disposed of $2,646,829,818 worth of shares (55,722,733 units at $47.50)
- SEC Form SC 13G filed by PPD, Inc.
- SEC Form 4: H&F Corporate Investors Viii, Ltd. sold $6,309,960,135 worth of shares (132,841,266 units at $47.50)
- SEC Form 4: H&F Corporate Investors Vii, Ltd. sold $6,309,960,135 worth of shares (132,841,266 units at $47.50)
- SEC Form 4: Johnston David Michael returned $1,681,832 worth of shares to the company (60,929 units at $27.60) and was granted 25,522 shares, closing all direct ownership in the company
- SEC Form 4: Hill Colin returned $775,675 worth of shares to the company (16,330 units at $47.50), closing all direct ownership in the company
- SEC Form 4: Kaucic Karen returned $398,620 worth of shares to the company (31,496 units at $12.66) and was granted 23,104 shares, closing all direct ownership in the company